Mankind Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Fri Apr 24 2026

Mankind Pharma (MANKIND) Q4 results for FY26 are expected in May 2026. With Q3 FY26 revenue of Rs 3250 Cr and PAT of Rs 618 Cr as the base, the street is watching closely for margin trajectory and management guidance on FY27 demand.

Get Free SEBI-Registered Research on Mankind Pharma â€” Click Here

Table of Contents

Mankind Pharma Q4 FY26 Earnings Preview â€” What to Expect

The pharma sector is expected to deliver solid Q4 FY26 performance with stabilising US generic pricing, robust domestic formulation growth and a deepening complex generics pipeline supporting both revenue and margin expansion.

Mankind Pharma Q4 Results 2026 â€” Date and Key Estimates

Parameter	Q3 FY26 Actual	Q4 FY26 Estimate	YoY Growth
Revenue (Rs Cr)	3250	3480	+7%
PAT (Rs Cr)	618	678	+10%
EBITDA Margin	—	19.5%	Improvement expected
Results Date	—	May 2026	—
Dividend History	Rs 5.00 per share
Dividend Expectation	Rs 7.00 final dividend expected

Estimates based on analyst consensus as of April 2026. Actual results may vary. Verify before investing.

Track Mankind Pharma live price, FII/DII activity and fundamentals on Univest Screener

5 Reasons Mankind Pharma Q4 Results Could Beat Estimates

US Generics Business Recovery

Pricing erosion in US generics has moderated significantly. New ANDA approvals and first-to-file opportunities in high-value molecules are providing meaningful revenue upside for companies with deep US pipelines.

Domestic Formulations Growth

India’s domestic pharma market continues growing at 9 to 11 percent, driven by chronic therapy categories including cardiovascular, diabetes and respiratory, and expanding healthcare access in semi-urban India.

API Segment Expansion via China Plus One

China Plus One sourcing diversification by global pharma companies is creating strong and durable demand for Indian API manufacturers with robust quality regulatory track records.

Complex Generics and Biosimilars Pipeline

Companies investing in complex injectables, biosimilars and specialty drugs are building differentiated pipelines that command significantly higher pricing and margins than standard generics.

Emerging Market Revenue Diversification

Africa, Latin America and Southeast Asia revenues are growing robustly, providing geographical diversification beyond the US and India and reducing single-market concentration risk.

5 Key Risks to Watch in Mankind Pharma Q4 Results

USFDA Inspection and Import Alert Risk

USFDA facility inspections and import alerts remain a persistent overhang; any adverse observation or warning letter can materially disrupt US revenues for multiple quarters.

US Generics Price Erosion

Competition from Chinese and domestic US manufacturers can re-intensify pricing pressure in base generics molecules, eroding volumes and realisations unexpectedly.

Raw Material Cost Pressure

API and solvent prices, particularly China-sourced intermediates, can spike and compress gross margins sharply if supply disruptions occur.

DPCO Price Control Impact

Inclusion of additional drugs in the National List of Essential Medicines limits domestic pricing flexibility and can restrict revenue growth for affected portfolios.

Currency Risk on Export Revenues

Weakness in export destination currencies against INR reduces international revenue realisation and compresses overseas profitability.

Analyst Ratings and Target Price for Mankind Pharma

Brokerage	Rating	Key Thesis
Bernstein	Outperform	US generics recovery and complex pipeline launches
CLSA	Buy	Domestic growth and API China Plus One opportunity
JM Financial	Buy	Margin expansion and emerging market revenue growth

Analyst ratings are for informational purposes only and subject to change. Not investment advice.

Mankind Pharma share price (MANKIND) is trading near Rs 2480 with a market capitalisation of approximately Rs 99,200 Cr. Track the stock on Univest Screener for live price and fundamental data.

Q4 Results 2026 Calendar â€” Key Dates to Track

Company	Expected Results Date
Mankind Pharma	May 2026
TCS	April 2026
Infosys	April 2026

Stay updated on all Q4 FY26 earnings at Univest Blogs. For TCS results see TCS Q4 Results 2026 and for Infosys see Infosys Q4 Results 2026.

How to Invest in Mankind Pharma Based on Q4 Results

Before investing in Mankind Pharma based on Q4 results, consider the following approach: review the actual revenue and PAT versus analyst estimates, listen to the management earnings call for FY27 guidance, assess whether the EBITDA margin trajectory is improving or deteriorating, and check FII/DII activity patterns post-results. A beat on estimates with positive guidance is typically a bullish signal; a miss with downgraded guidance may indicate further correction risk.

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss levels on Mankind Pharma â€” Click Here

Frequently Asked Questions â€” Mankind Pharma Q4 Results 2026

Q: When will Mankind Pharma announce Q4 FY26 results?

Mankind Pharma (MANKIND) is expected to announce Q4 FY26 results in May 2026. The exact board meeting date will be communicated via BSE/NSE exchange filing. Track the date on Univest Screener.

Q: What is the revenue estimate for Mankind Pharma Q4 FY26?

Analyst consensus estimates Mankind Pharma Q4 FY26 revenue at approximately Rs 3480 Cr, representing approximately 7% year-on-year growth. The actual number will depend on sector demand trends and execution in the quarter.

Q: What PAT is expected for Mankind Pharma in Q4 FY26?

Estimated PAT for Mankind Pharma Q4 FY26 is approximately Rs 678 Cr, up approximately 10% year-on-year. Margin expansion from operating leverage and input cost moderation are the primary drivers of profit growth expectations.

Q: Will Mankind Pharma declare a dividend in Q4 FY26?

Historical dividend pattern for Mankind Pharma: Rs 5.00 per share. For Q4 FY26, Rs 7.00 final dividend expected. Dividend declarations are subject to board approval at the time of results.

Q: What is the current share price and market cap of Mankind Pharma?

Mankind Pharma (MANKIND) is currently trading at approximately Rs 2480 with a market capitalisation of Rs 99,200 Cr. Track live price, volume and FII/DII data on Univest Screener.

Q: What are the key risks for Mankind Pharma in Q4 FY26?

Key risks include: USFDA Inspection and Import Alert Risk, US Generics Price Erosion, Raw Material Cost Pressure. Investors should monitor management commentary on these risks in the Q4 earnings call.

Q: Is Mankind Pharma a buy before Q4 results?

This article does not constitute investment advice. Whether to buy Mankind Pharma before Q4 results depends on your risk appetite, existing portfolio exposure and entry price relative to fair value. Consult a SEBI-registered financial advisor before making any investment decision.

Q: How can I track Mankind Pharma Q4 results live?

Track Mankind Pharma Q4 FY26 results live on the Univest Screener, which provides real-time price updates, financial data and analyst research. Download the Univest iOS App or Android App for mobile alerts.

Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decisions. SEBI Registration: INH000012449.